REUTERS: The U.S. Food and Drug Administration has approved Intra-Cellular Therapies Inc's investigational drug to treat schizophrenia, the company said on Monday.
The treatment, Caplyta, is the drug developer's lead candidate that has shown to regulate three neurotransmitter systems associated to severe mental illnesses - serotonin, dopamine and glutamate.Schizophrenia is a chronic mental disorder that causes distortion in thoughts, hallucinations and feelings of fright and paranoia.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »